Climb Bio, Inc. (CLYM)
NASDAQ: CLYM · Real-Time Price · USD
1.275
-0.005 (-0.39%)
Mar 31, 2025, 1:31 PM EDT - Market open
Climb Bio Employees
As of December 31, 2023, Climb Bio had 11 total employees, including 9 full-time and 2 part-time employees. The number of employees decreased by 32 or -74.42% compared to the previous year.
Employees
11
Change (1Y)
-32
Growth (1Y)
-74.42%
Revenue / Employee
n/a
Profits / Employee
-$6,717,909
Market Cap
86.03M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 11 | -32 | -74.42% |
| Dec 31, 2022 | 43 | 12 | 38.71% |
| Dec 31, 2021 | 31 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CLYM News
- 4 days ago - Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 5 days ago - Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 4 weeks ago - Climb Bio to Present at Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer - GlobeNewsWire
- 7 weeks ago - Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 2 months ago - Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy - GlobeNewsWire
- 3 months ago - Climb Bio to be Added to the Nasdaq Biotechnology Index - GlobeNewsWire
- 4 months ago - Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire